Predictors of autosomal dominant polycystic kidney disease progression. 2014

Robert W Schrier, and Godela Brosnahan, and Melissa A Cadnapaphornchai, and Michel Chonchol, and Keith Friend, and Berenice Gitomer, and Sandro Rossetti
Division of Renal Diseases and Hypertension, University of Colorado School of Medicine, Aurora, Colorado; and robert.schrier@ucdenver.edu.

Autosomal dominant polycystic kidney disease is a genetic disorder associated with substantial variability in its natural course within and between affected families. Understanding predictors for rapid progression of this disease has become increasingly important with the emergence of potential new treatments. This systematic review of the literature since 1988 evaluates factors that may predict and/or effect autosomal dominant polycystic kidney disease progression. Predicting factors associated with early adverse structural and/or functional outcomes are considered. These factors include PKD1 mutation (particularly truncating mutation), men, early onset of hypertension, early and frequent gross hematuria, and among women, three or more pregnancies. Increases in total kidney volume and decreases in GFR and renal blood flow greater than expected for a given age also signify rapid disease progression. Concerning laboratory markers include overt proteinuria, macroalbuminuria, and perhaps, elevated serum copeptin levels in affected adults. These factors and others may help to identify patients with autosomal dominant polycystic kidney disease who are most likely to benefit from early intervention with novel treatments.

UI MeSH Term Description Entries
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D011237 Predictive Value of Tests In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test. Negative Predictive Value,Positive Predictive Value,Predictive Value Of Test,Predictive Values Of Tests,Negative Predictive Values,Positive Predictive Values,Predictive Value, Negative,Predictive Value, Positive
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D016891 Polycystic Kidney, Autosomal Dominant Kidney disorders with autosomal dominant inheritance and characterized by multiple CYSTS in both KIDNEYS with progressive deterioration of renal function. Autosomal Dominant Polycystic Kidney,Kidney, Polycystic, Autosomal Dominant,ADPKD,Adult Polycystic Kidney Disease,Adult Polycystic Kidney Disease Type 1,Adult Polycystic Kidney Disease Type 2,Polycystic Kidney Disease 2,Polycystic Kidney Disease, Adult,Polycystic Kidney Disease, Adult Type 2,Polycystic Kidney Disease, Adult, Type II,Polycystic Kidney Disease, Autosomal Dominant,Polycystic Kidney Disease, Type 2,Polycystic Kidney, Type 1 Autosomal Dominant Disease,Polycystic Kidney, Type 2 Autosomal Dominant Disease
D050396 TRPP Cation Channels A subgroup of TRP cation channels that are widely expressed in various cell types. Defects are associated with POLYCYSTIC KIDNEY DISEASES. Polycystin,Polycystins,Cation Channels, TRPP,Channels, TRPP Cation
D018450 Disease Progression The worsening and general progression of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis. Clinical Course,Clinical Progression,Disease Exacerbation,Exacerbation, Disease,Progression, Clinical,Progression, Disease

Related Publications

Robert W Schrier, and Godela Brosnahan, and Melissa A Cadnapaphornchai, and Michel Chonchol, and Keith Friend, and Berenice Gitomer, and Sandro Rossetti
September 2021, Pediatric nephrology (Berlin, Germany),
Robert W Schrier, and Godela Brosnahan, and Melissa A Cadnapaphornchai, and Michel Chonchol, and Keith Friend, and Berenice Gitomer, and Sandro Rossetti
February 2017, Minerva medica,
Robert W Schrier, and Godela Brosnahan, and Melissa A Cadnapaphornchai, and Michel Chonchol, and Keith Friend, and Berenice Gitomer, and Sandro Rossetti
September 2021, Pediatric nephrology (Berlin, Germany),
Robert W Schrier, and Godela Brosnahan, and Melissa A Cadnapaphornchai, and Michel Chonchol, and Keith Friend, and Berenice Gitomer, and Sandro Rossetti
January 2019, American journal of nephrology,
Robert W Schrier, and Godela Brosnahan, and Melissa A Cadnapaphornchai, and Michel Chonchol, and Keith Friend, and Berenice Gitomer, and Sandro Rossetti
October 2001, Lancet (London, England),
Robert W Schrier, and Godela Brosnahan, and Melissa A Cadnapaphornchai, and Michel Chonchol, and Keith Friend, and Berenice Gitomer, and Sandro Rossetti
January 2017, Contributions to nephrology,
Robert W Schrier, and Godela Brosnahan, and Melissa A Cadnapaphornchai, and Michel Chonchol, and Keith Friend, and Berenice Gitomer, and Sandro Rossetti
August 2012, Clinical and experimental nephrology,
Robert W Schrier, and Godela Brosnahan, and Melissa A Cadnapaphornchai, and Michel Chonchol, and Keith Friend, and Berenice Gitomer, and Sandro Rossetti
December 1997, Kidney international. Supplement,
Robert W Schrier, and Godela Brosnahan, and Melissa A Cadnapaphornchai, and Michel Chonchol, and Keith Friend, and Berenice Gitomer, and Sandro Rossetti
May 2001, Kidney international,
Robert W Schrier, and Godela Brosnahan, and Melissa A Cadnapaphornchai, and Michel Chonchol, and Keith Friend, and Berenice Gitomer, and Sandro Rossetti
November 2015, Nature reviews. Nephrology,
Copied contents to your clipboard!